Get the Stockscreener App
7.36
0.14%
+0.01
Profound Medical Corp stock is currently priced at $7.36, with a 24-hour trading volume of 8,257.
It has seen a +0.14% increased in the last 24 hours and a -12.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.37 pivot point. If it approaches the $7.28 support level, significant changes may occur.
Previous Close:
$7.35
Open:
$7.3925
24h Volume:
8,257
Market Cap:
$179.80M
Revenue:
$7.20M
Net Income/Loss:
$-28.57M
P/E Ratio:
-5.3723
EPS:
-1.37
Net Cash Flow:
$-22.30M
1W Performance:
-8.34%
1M Performance:
-12.38%
6M Performance:
-23.33%
1Y Performance:
-41.45%
1D Range:
$7.33
$7.5971
52W Range:
$7.11
$15.49
Profound Medical Corp Stock (PROF) Company Profile
Name
Profound Medical Corp
Sector
Industry
Phone
647 476 1350
Address
2400 Skymark Avenue, Unit no. 6, Mississauga, ON
Profound Medical Corp Stock (PROF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-21-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-15-20 | Initiated | Jefferies | Buy |
Profound Medical Corp Stock (PROF) Latest News
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
GlobeNewswire Inc.
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire Inc.
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
GlobeNewswire Inc.
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
Zacks Investment Research
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
GlobeNewswire Inc.
Profound Medical Corp Stock (PROF) Financials Data
Profound Medical Corp (PROF) Revenue 2024
PROF reported a revenue (TTM) of $7.20 million for the quarter ending December 31, 2023, a +7.75% rise year-over-year.
Profound Medical Corp (PROF) Net Income 2024
PROF net income (TTM) was -$28.57 million for the quarter ending December 31, 2023, a +0.35% increase year-over-year.
Profound Medical Corp (PROF) Cash Flow 2024
PROF recorded a free cash flow (TTM) of -$22.30 million for the quarter ending December 31, 2023, a +13.58% increase year-over-year.
Profound Medical Corp (PROF) Earnings per Share 2024
PROF earnings per share (TTM) was -$1.35 for the quarter ending December 31, 2023, a +2.17% growth year-over-year.
About Profound Medical Corp
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
0.77%
Cap:
|
Volume (24h):